相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of comprehensiveDNAdamage repair gene germline mutations in Chinese prostate cancer patients
Junlong Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing
Liancheng Fan et al.
JOURNAL OF UROLOGY (2021)
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Yongliang Zhang et al.
NATURE COMMUNICATIONS (2021)
Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls
Yukihide Momozawa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Elie Ritch et al.
CLINICAL CANCER RESEARCH (2020)
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Yingming Li et al.
CLINICAL CANCER RESEARCH (2020)
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive for Prostate Cancer
Konrad H. Stopsack et al.
CLINICAL CANCER RESEARCH (2020)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke et al.
EUROPEAN UROLOGY (2020)
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
Meijun Du et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Manish Kohli et al.
EBIOMEDICINE (2020)
A genomic and epigenomic atlas of prostate cancer in Asian populations
Jing Li et al.
NATURE (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer
Yu Wei et al.
ONCOLOGIST (2020)
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer
Umang Swami et al.
EUROPEAN UROLOGY (2020)
Racial Differences in Genomic Profiling of Prostate Cancer
Brandon A. Mahal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing
Naveen Ramesh et al.
GENOME BIOLOGY (2020)
An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer
Vincent Faugeroux et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Marthe Lovf et al.
EUROPEAN UROLOGY (2019)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
William S. Chen et al.
EUROPEAN UROLOGY (2019)
Germline and Somatic Mutations in Prostate Cancer for the Clinician
Heather H. Cheng et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality
Robert T. Dess et al.
JAMA ONCOLOGY (2019)
Clinical features of neuroendocrine prostate cancer
Vincenza Conteduca et al.
EUROPEAN JOURNAL OF CANCER (2019)
Towards precision oncology in advanced prostate cancer
Sheng-Yu Ku et al.
NATURE REVIEWS UROLOGY (2019)
Role of Androgen Receptor in Prostate Cancer: A Review
Kazutoshi Fujita et al.
WORLD JOURNAL OF MENS HEALTH (2019)
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
Lisanne F. van Dessel et al.
NATURE COMMUNICATIONS (2019)
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
Guru Sonpavde et al.
CANCER (2019)
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Vincenza Conteduca et al.
EUROPEAN UROLOGY (2019)
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
Anis A. Humid et al.
EUROPEAN UROLOGY (2019)
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Gillian Vandekerkhove et al.
EUROPEAN UROLOGY (2019)
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
CLINICAL CANCER RESEARCH (2019)
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
Takayuki Sumiyoshi et al.
SCIENTIFIC REPORTS (2019)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease
Martina Mijuskovic et al.
BRITISH JOURNAL OF CANCER (2018)
The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression
Shadrielle Melijah G. Espiritu et al.
CELL (2018)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley et al.
CELL (2018)
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
Srinivas R. Viswanathan et al.
CELL (2018)
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
Jelena Belic et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
Matteo Allegretti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients
Manish Kohli et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Daniel Nava Rodrigues et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Markus Mayrhofer et al.
GENOME MEDICINE (2018)
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen et al.
CLINICAL CANCER RESEARCH (2018)
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
Atish D. Choudhury et al.
JCI INSIGHT (2018)
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone
L. Wang et al.
ANNALS OF ONCOLOGY (2018)
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na et al.
EUROPEAN UROLOGY (2017)
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
Bram De laere et al.
EUROPEAN UROLOGY (2017)
Genomic hallmarks of localized, non-indolent prostate cancer
Michael Fraser et al.
NATURE (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks
Alice Guyard et al.
VIRCHOWS ARCHIV (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors
Brennan Decker et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar et al.
NATURE MEDICINE (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
Peter Ulz et al.
NATURE COMMUNICATIONS (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Paul C. Boutros et al.
NATURE GENETICS (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis-A Systematic Review and Pooled Analysis
Hai Tao Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Copy number alteration burden predicts prostate cancer relapse
Haley Hieronymus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants
Jian An et al.
CELL REPORTS (2014)
Punctuated Evolution of Prostate Cancer Genomes
Sylvan C. Baca et al.
CELL (2013)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Ellen Heitzer et al.
GENOME MEDICINE (2013)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Christopher E. Barbieri et al.
NATURE GENETICS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians
Tomomi Kimura
CHINESE JOURNAL OF CANCER (2012)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis
Xueying Mao et al.
CANCER RESEARCH (2010)
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples
Yohei Miyagi et al.
MODERN PATHOLOGY (2010)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Molecular genetics of prostate cancer
C Abate-Shen et al.
GENES & DEVELOPMENT (2000)
分享论文
